How Biosimilars Could Lower Part D Costs for Seniors
Juliana M. Reed, MS, of the Biosimilars Forum says reference biologics outnumber biosimilars 2:1 in Medicare despite steep discounts.
Will PBM Rebate Reform Help Biosimilars Win Formulary Spots?
Juliana M. Reed, MS, of the Biosimilars Forum says employers must watch what replaces rebates under CAA 2026 PBM reforms.
Irish Oncology Drug Costs Rose Over 3100% as Biosimilar Uptake Lagged
A commentary on Irish oncology spending finds hospital drug costs rose more than 3100% in under a decade, while biosimilar uptake remained low.
IGBA's Global Biosimilars Week Panel Spotlights Value of Access
Panelists at an IGBA Global Biosimilars Week webinar detailed worldwide access gains and adoption barriers.
Biosimilar Uptake in Europe Reached 40.7%, With Wide Country Gaps
Biosimilar market share averaged 40.7% across 27 European countries by mid-2024, with gain-sharing, switching, and quotas linked to higher uptake.
National Tendering, Combined Policies Linked to Highest Biosimilar Uptake
Highest biosimilar uptake occurred where policymakers combined multiple supply- and demand-side measures or ran coordinated national tendering.
Ustekinumab Biosimilar Switch Holds Up in Crohn Disease
A prospective Italian cohort found procurement-driven switching from reference ustekinumab to biosimilars preserved remission and safety in Crohn disease.
Biosimilar Bills Would Automate Medicare Negotiation Delays
Bipartisan bills would automatically delay Medicare price talks for biologics facing biosimilars as California expands substitution.
How FDA's PK Guidance Shapes Teva's Next Biosimilar Program
Robert Cook, PhD, of Teva explains how analytical characterization and PK data will shape its next biosimilar program.
Inside Teva's Denosumab Biosimilar Strategy: Robert Cook, PhD
Teva's Robert Cook, PhD, explains the clinical data, interchangeability, and supply strategy behind its Degevma and Ponlimsi biosimilars.
Teva Completes Denosumab Biosimilar Pair With FDA Nod for Degevma
The FDA approved Teva's Degevma, a denosumab biosimilar to Xgeva for cancer-related bone disease, rounding out its Xgeva/Prolia portfolio.
Generic, Biosimilar Medicines Saved US Health Care $496B in 2025
The Association for Accessible Medicines report, prepared with the IQVIA Institute, also reports $25.4 billion in biosimilar savings for the year.
Infliximab Biosimilar Maintains Remission, Trough Levels After Switch in IBD
A Japanese study found high remission and continuation rates, plus non-inferior trough levels, after patients with IBD were switched to the infliximab biosimilar CT-P13.
Biosimilar Denosumab Could Reshape Access, Costs in Osteoporosis Care: Edward Li, PharmD
Sandoz's Edward Li explains how biosimilar denosumab pricing could reshape cost-effectiveness, payer access, and gaps in osteoporosis care.
Step Therapy to Biosimilars, Branded Anti-VEGF Costs More, Data Show
Bevacizumab-to-biosimilar-to-branded transitions delayed nAMD care and cost more than direct switches.
Natalizumab Biosimilar Shows Limited Cost-Effectiveness in MS
A study found no direct trial evidence for natalizumab or its biosimilar in MS and found limited cost-effectiveness vs most alternatives.
Nonmedical Adalimumab Biosimilar Switch Maintains Disease Control in Pediatric IBD
Most pediatric and young adult patients with IBD maintained stable disease activity and laboratory markers after switching from the adalimumab originator.
Rituximab Biosimilars Show Comparable 6-Month Outcomes in AAV
Rituximab biosimilars showed no significant 6-month differences vs the originator in antineutrophil cytoplasmic antibody–associated vasculitis (AAV).
Analytical Characterization Supports Confidence in Monoclonal Antibody Biosimilars
Analytical characterization supports monoclonal antibody biosimilar approvals and may reduce clinical testing needs, researchers found.
Biosimilar Denosumab Shows Cost-Effectiveness Over Bisphosphonates in PMO
Biosimilar denosumab cleared a $150,000 per QALY cost-effectiveness threshold against bisphosphonates for high-risk PMO, but not always at $100,000.
Denosumab Biosimilar KN012 Matches Reference Drug in Phase 3 Osteoporosis Trial
KN012 achieved BMD equivalence with US-approved denosumab in postmenopausal women in China.
Eculizumab Biosimilar Shows Durable Benefit in Long-Term aHUS
A 50-patient study found sustained platelet recovery and low thrombotic microangiopathy rates through 52 weeks of biosimilar therapy, with favorable safety.
Biosimilar Bills Gain Steam in Congress, But Key Reforms Still Wait
Congress fast-tracks biosimilar bills to cut drug and insulin costs, while patent, rebate, and reimbursement roadblocks still stall competition.
Aflibercept Biosimilar SB15 Shows Real-World Efficacy Across Retinal Diseases
Aflibercept biosimilar SB15 improved retinal anatomy while preserving vision in both treatment-naïve and switching patients with nAMD, RVO, and DME.
Biosimilar Ranibizumab Performs on Par With Innovator Drug Across Retinal Diseases
Nearly 5000 eyes and nearly 21,000 injections show comparable vision, anatomical, and safety outcomes between biosimilar ranibizumab and the innovator drug.
Real-World Natalizumab Biosimilar Switch Reduced Treatment Satisfaction Despite Stable Outcomes
Real-world natalizumab biosimilar switching preserved relapsing-remitting MS outcomes but lowered treatment satisfaction, likely due to a nocebo effect.
Romosozumab Biosimilar Matches Reference in Functional Testing Despite Disulfide Differences
A romosozumab biosimilar showed comparable sclerostin binding and bone-signaling potency to the reference product despite disulfide isoform differences.
FDA Accepts Sandoz Generic Tirzepatide Applications Amid Biosimilar Development Gap
Sandoz moves toward US generic tirzepatide autoinjectors as FDA reviews ANDAs, signaling future GLP‑1 access amid patent and biosimilar gaps.
Anti-VEGF Biosimilars Match Reference Drug in Indian Retinal Disease Care
Biosimilar anti-VEGF agents matched the reference ranibizumab in vision outcomes and safety across retinal diseases in India, at a lower cost.
Rituximab Biosimilar Reached 75% Remission, Matched Innovator in Membranous Nephropathy
Real-world data shows rituximab biosimilars for membranous nephropathy match remission rates, cut costs, and expand treatment options.